title: 'The pump was a saviour for me.' Patients' experiences of insulin pump therapy.
abstract: OBJECTIVE
  The present study formed part of a larger study examining the potential long-term effects of glycaemic control and treatment satisfaction in people with Type 1 diabetes mellitus who changed from multiple daily insulin injections to insulin pump therapy. Individuals (n = 46) who made the transition between May 1999 and February 2004 participated. The aim of the study was to describe experiences of the impact of insulin pump therapy in adults with Type 1 diabetes mellitus after > 5 years' use of an insulin pump.
  
  
  METHODS
  During spring 2009, 16 of the individuals were interviewed through a narrative approach on the effects of insulin pump therapy on daily life. The interviews were analysed using content analysis.
  
  
  RESULTS
  The overarching theme revealed that insulin pump therapy was experienced as both a shackle and a lifeline. Six sub-themes emerged: subjected vs. empowered; dependent vs. autonomous; vulnerable vs. strengthened; routinized vs. flexible; burdened vs. relieved; and stigmatized vs. normalized.
  
  
  CONCLUSIONS
  Users of insulin pump therapy have different views about and experience of having used the technical equipment over years. Both positive and negative views emerged. However, it is difficult to identify any general trends that cover all views and can predict which individuals will be able to manage pump therapy in the best way. Even so, the sub-themes and theme that emerged could be used by physicians and diabetes specialist nurses when counselling and planning educational programmes aimed at supporting self-management among people with insulin pump treatment.
authors: School of Health and Social Studies, Dalarna University, Umeå, Sweden. anna.garmo@ltdalarna.se
authors: A
authors: A
authors: Garmo
authors: Å
authors: Å
authors: Hörnsten
authors: J
authors: J
authors: Leksell
mesh_terms: D000328:Adult; D000368:Aged; D001294:Attitude to Health; D017281:Cost of Illness; D003430:Cross-Sectional Studies; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000188:drug therapy*; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D006943:Hyperglycemia / Q000517:prevention & control*; D007003:Hypoglycemia / Q000517:prevention & control*; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D007328:Insulin / Q000008:administration & dosage* / Q000627:therapeutic use; D007332:Insulin Infusion Systems / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D010044:Outpatient Clinics, Hospital; D017060:Patient Satisfaction; D011788:Quality of Life; D013548:Sweden
chemical_list: D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin; C517652:hemoglobin A1c protein, human